98%
921
2 minutes
20
The abundant, nuclear-retained, metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been associated with a poorly differentiated and aggressive phenotype of mammary carcinomas. This long non-coding RNA (lncRNA) localizes to nuclear speckles, where it interacts with a subset of splicing factors and modulates their activity. In this study, we demonstrate that oncogenic splicing factor SRSF1 bridges MALAT1 to mutant p53 and ID4 proteins in breast cancer cells. Mutant p53 and ID4 delocalize MALAT1 from nuclear speckles and favor its association with chromatin. This enables aberrant recruitment of MALAT1 on VEGFA pre-mRNA and modulation of VEGFA isoforms expression. Interestingly, VEGFA-dependent expression signatures associate with ID4 expression specifically in basal-like breast cancers carrying mutations. Our results highlight a key role for MALAT1 in control of VEGFA isoforms expression in breast cancer cells expressing gain-of-function mutant p53 and ID4 proteins.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5538427 | PMC |
http://dx.doi.org/10.15252/embr.201643370 | DOI Listing |
Clin Chim Acta
August 2025
Division of Clinical Laboratory, Gifu University Hospital, Gifu, Japan; Department of Cardiology, Gifu University Graduate School of Medicine, Gifu, Japan.
Background: Sex differences significantly affect many laboratory test results. However, sex differences in the serum and urine levels of the major vascular endothelial growth factor-A (VEGF-A) isoforms, VEGF-A and VEGF-A, remain unclear. This study aimed to assess these sex-based profiles using a newly developed assay system.
View Article and Find Full Text PDFBiol Res
August 2025
Instituto de Bioquímica y Microbiología, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile.
Background: Gallbladder cancer (GBC) is a highly lethal malignancy, often diagnosed at advanced stages when curative options are limited. Its rapid progression and high metastatic potential result in a 5-year survival rate below 5%. Recent evidence highlights the role of Endothelin-1 (ET1), a bioactive peptide, in promoting tumor aggressiveness through activation of its receptors (ETRs).
View Article and Find Full Text PDFSci Rep
July 2025
Izmir Biomedicine and Genome Center, 35340, Izmir, Türkiye.
Vascular Endothelial Growth Factor (VEGF) plays important roles in the pathogenesis of age-related macular degeneration (AMD), the most common cause of vision loss in the elderly. Intravitreal anti-VEGF injection is the gold standard for AMD treatment. Here three novel anti-VEGF single chain variable fragments (scFvs) produced in Pichia pastoris system are reported.
View Article and Find Full Text PDFMol Pharm
September 2025
Pharmaceutical Sciences, Roche Innovation Center Basel, Roche Pharma Research and Early Development, 4070 Basel, Switzerland.
Targeting VEGF is an established therapeutic strategy for several retinal diseases; however, gaps in understanding the kinetic behavior of VEGF in the eye hinder the interpretation of anti-VEGF pharmacokinetic/pharmacodynamic data. This study aimed to investigate the ocular kinetics, biodistribution, and biological effects of human VEGF isoforms 121 and 165. Thirty rabbits received single intravitreal injections across a 100-fold dose range (0.
View Article and Find Full Text PDFPLoS Comput Biol
July 2025
Institute for Computational Medicine and Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, United States of America.
The vascular endothelial growth factor receptors (VEGFRs) bind to cognate ligands to facilitate signaling pathways critical for angiogenesis, the growth of new capillaries from existing vasculature. Intracellular trafficking regulates the availability of receptors on the cell surface to bind ligands, which regulate activation, and the movement of activated receptors between the surface and intracellular pools, where they can initiate different signaling pathways. Using experimental data and computational modeling, we recently demonstrated and quantified the differential trafficking of three VEGF receptors, VEGFR1, VEGFR2, and coreceptor Neuropilin-1 (NRP1).
View Article and Find Full Text PDF